Finally, many of Jim's investment recommendations are indeed nuanced and qualified. Treating every investment recommendation as the same and compiling an investment performance is, to some degree, comparing apples to oranges.

In my final analysis, individual investors are better served listening to Jim Cramer, both with regard to his recommendations and his methodology, than any other business commentator extant. His body of investment knowledge is remarkably broad and lacks the superficiality of most of his brethren.

Jim is an investment populist who, unlike many in my hedge fund cabal, has forsaken that financial rainbow for a greater cause -- namely, helping out the individual investor.

Jim is an easy target, but from my perch, he should not be vilified; he should be admired. has a revenue-sharing relationship with under which it receives a portion of the revenue from Amazon purchases by customers directed there from

Doug Kass writes daily for RealMoney Silver , a premium bundle service from For a free trial to RealMoney Silver and exclusive access to Mr. Kass's daily trading diary, please click here.

Know What You Own: Doug Kass mentions Jim Cramer's stock picks, and some of the top-performing stocks in Cramer's Action Alerts PLUS portfolio include Bristol-Myers Squibb (BMY), Abbott Laboratories (ABT), Gilead Sciences (GILD), BP (BP), iShares FTSE/Xinhua China 25 Index (FXI), ConocoPhillips (COP) and Johnson & Johnson (JNJ). For more on the value of knowing what you own, visit's Investing A-to-Z section.
At the time of publication, Kass and/or his funds had no positions in the stocks mentioned, although holdings can change at any time.

Doug Kass is founder and president of Seabreeze Partners Management, Inc., and the general partner and investment manager of Seabreeze Partners Short LP and Seabreeze Partners Long/Short LP.

If you liked this article you might like

Bristol-Myers Squibb Stock Still a Beast?

There Are Good Opportunities in Stock Picking

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Achillion Shares Are Plunging on Termination of Hepatitis C Pact